Overview

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Status:
Not yet recruiting

Trial end date:
2026-06-30

Target enrollment:

Participant gender:

Summary

Although immune checkpoint inhibitors (ICIs) provide a durable response in multiple tumor types, relapse occurs in most patients with solid tumor. However, the benefits of retreatment with ICIs remains controversial. In some studies, retreatment with ICIs has exhibited encouraging efficacy in patients with solid tumors, particularly in melanoma, and non-small cell lung cancer (NSCLC). In this single arm phase 2 trial, we aimed to evaluate the efficacy and safety of the combination of anti-PD1 antibody (zimberelimab) and lenvatinib in patients with advanced cervical cancer who progressed on or after prior ICIs.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Lenvatinib